Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $45.8 million.

  • Cytosorbents' Liabilities and Shareholders Equity fell 429.67% to $45.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.9 million, marking a year-over-year decrease of 465.28%. This contributed to the annual value of $47.4 million for FY2024, which is 1054.51% down from last year.
  • Cytosorbents' Liabilities and Shareholders Equity amounted to $45.8 million in Q3 2025, which was down 429.67% from $48.0 million recorded in Q2 2025.
  • Cytosorbents' 5-year Liabilities and Shareholders Equity high stood at $98.2 million for Q2 2021, and its period low was $45.8 million during Q3 2025.
  • For the 5-year period, Cytosorbents' Liabilities and Shareholders Equity averaged around $63.2 million, with its median value being $53.4 million (2024).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 9934.1% in 2021, then crashed by 3449.96% in 2022.
  • Cytosorbents' Liabilities and Shareholders Equity (Quarter) stood at $89.5 million in 2021, then dropped by 29.37% to $63.2 million in 2022, then dropped by 16.25% to $53.0 million in 2023, then fell by 10.55% to $47.4 million in 2024, then fell by 3.42% to $45.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $45.8 million for Q3 2025, versus $48.0 million for Q2 2025 and $50.8 million for Q1 2025.